Skip to main content
SpringerLink
Log in

Beeinflusst die Verdünnung das kosmetische Ergebnis von BoNT/A?

Komplexproteinfreies BoNT/A zur Behandlung der Glabellafalte

Does dilution have an impact on cosmetic results with BoNT/A?

Complex-protein-free BoNT/A for treatment of glabella lines

  • Originalien
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Ziel der vorliegenden 2-armigen, randomisierten Pilotstudie war die Prüfung der Wirksamkeit und Verträglichkeit von 2 verschiedenen Verdünnungen eines Botulinum-Neurotoxin Typ A ohne Komplexproteine (BoNT/A) bei der Behandlung der Glabellafalte.

Patienten und Methodik

Es wurden 40 Patienten mit Glabellafalten der Faltenstärke 2–3 nach Facial Wrinkle Scale mit 25 Units BoNT/A (Xeomin®) behandelt. Hierfür wurden 100 Units BoNT/A in 2,5 ml (Gruppe I) oder 4,0 ml NaCl-Lösung (Gruppe II) aufgelöst. Responder zeigten eine Verbesserung im Faltenscore (unabhängiger Untersucher) um mindestens 1 Punkt.

Ergebnisse

Die Responderzahlen betrugen nach 2 Wochen 100/89,5%, nach 3 Monaten 84,2/64,7% und nach 4 Monaten 53,3/61,5% (jeweils Gruppe I/II). Es zeigte sich kein signifikanter Unterschied zwischen den Verdünnungen.

Schlussfolgerungen

Botulinum-Neurotoxin Typ A ohne Komplexproteine reduziert in beiden getesteten Verdünnungen die Ausprägung der Glabellafalte. Es ist kein statistischer Unterschied in der Effizienz der Behandlung mit unterschiedlichen Verdünnungen nachweisbar.

Abstract

Background

In this 2-armed, randomized study we investigated the efficacy and tolerability of complex-protein-free botulinum neurotoxin type A (BoNT/A), applied in two different dilution volumes for treatment of glabellar lines.

Patients and methods

40 patients with grade 2–3 glabellar lines (Facial Wrinkle Scale) received treatment with 25U BoNT/A (Xeomin®). 100U of botulinum neurotoxin were diluted in 2.5ml (group I) or 4ml sodium chloride solution (group II). Responders showed an improvement in the wrinkle score (independent rater) of at least one point.

Results

Response rates two weeks after treatment were 100% / 89.5%, at 3 months 84.2% / 64.7% and at 4 months 53.3% / 61.5% (groups I / II respectively). There was no significant difference between the two dilutions.

Conclusion

Complex-protein-free botulinum neurotoxin type A in both dilutions effectively reduced severity of glabellar lines. There was no statistically significant difference in efficacy between the two dilutions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7

Literatur

  1. Ascher B, Zakine B, Kestemont P et al (2004) A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 51:223–233

    Article  PubMed  Google Scholar 

  2. Benecke R, Jost WH, Kanovsky P et al (2005) A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64:1949–1951

    Article  PubMed  CAS  Google Scholar 

  3. Bigalke H (2001) Botulinum Toxine: Wirksamkeit und Antigenität. Klin Neurophysiol 32:210–212

    Article  Google Scholar 

  4. Blümel J, Frevert J Schwaier A (2006) Comparative antigenicity of three preparations of botulinum neurotoxin type a in the rabbit. Neurotox Res 9(2–3):238

    Google Scholar 

  5. Borodic G (2006) Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg 22(3):239–240

    Article  PubMed  Google Scholar 

  6. Carruthers A, Carruthers J, Cohen J (2007) Dilution volume of botulinum toxin type a for the treatment of glabellar rhytides: does it matter? Dermatol Surg 33:S97–S104

    Article  PubMed  CAS  Google Scholar 

  7. Carruthers J, Fagien S, Matarasso SL, the Botox Consensus Group (2004) Consensus recommendations on the use of botulinum txine type Ain facial aesthetics. Plast Reconstr Surg 114 (Suppl 6):1–22

    Article  Google Scholar 

  8. Carruthers JD, Lowe NJ, Menter MA et al (2003) Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112:1089–1098

    Article  PubMed  Google Scholar 

  9. Carruthers JD, Lowe NJ, Menter MA et al (2002) A multicenter, double-blind, randomized, placebo-controlledstudy of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849

    Article  PubMed  Google Scholar 

  10. Carruthers JD, Lowe NJ, Menter MA et al (2004) One-year, randomisid, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabella lines. J Clin Res 7:1–20

    Google Scholar 

  11. Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19 (Suppl 8):S92–S100

    Article  PubMed  Google Scholar 

  12. Dressler D, Rothwell JC (2000) Elektromyographic quantfication of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43:13–16

    Article  PubMed  CAS  Google Scholar 

  13. Francisco GE, Boake C, Vaughn A (2002) Botulinum toxin in upper limb spasticity after acquired brain injury:a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 81:3545–3563

    Article  Google Scholar 

  14. Göschel H, Wohlfarth K, Frevert J et al (1997) Botulinum A toxin therapy:neutralizing and nonneutralizing antibodies–therapeutic consequences. Exp Neurol 147:96–102

    Article  PubMed  Google Scholar 

  15. Hsu TSJ, Dover JS, Arndt KA (2004) Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140:1351–1354

    Article  PubMed  CAS  Google Scholar 

  16. Jost WH, Blümel J, Grafe S (2007) Botulinum neurotoxin type A free of complexing proteins (Xeomin®) in focal dystonia. Drugs 67:669–683

    Article  PubMed  CAS  Google Scholar 

  17. Khorram R (2006) Faltentherapie mit einem neuen deproteinisierten Botulinumtoxin A (Xeomin®) bei 40 Patienten. Plastische Chirurgie 6 (Suppl 1):55

    Google Scholar 

  18. Klein AW (1998) Dilution and storage of botulinum toxin. Dermatol Surg 24:1179–1180

    Article  PubMed  CAS  Google Scholar 

  19. Lee SK (2007) Antibody-Induced failure of botulinum toxin type a therapy in a patient with masseteric hypertrophy. Dermatol Surg 33:S105–S110

    Article  PubMed  CAS  Google Scholar 

  20. Lowe NJ, Ascher B, Heckmann M et al (2005) Botox Facial Aesthetic Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crows feet. Dermatol Surg 31:257–262

    Article  PubMed  CAS  Google Scholar 

  21. Lowe NJ, Yamauchi PS, Lask GP et al (2002) Botulinum toxins types A and B for brow furrows:preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4:15–18

    Article  PubMed  Google Scholar 

  22. Maack M, Krüger J, Bayrhammer J et al (2007) Beeinflussen Komplexproteine das Diffusionsverhalten. Dtsch Dermatologe 55(8):562–563

    Google Scholar 

  23. Prager W, Zschocke I, Turnbull K, Steinkraus V (2007) Wirksamkeit und Verträglichkeit des neuen, komplexproteinfreien Botulinumtoxins (Xeomin®) bei der Behandlung von mimischen Falten – Untersuchungsergebnisse. Kosmetische Medizin 2:81–84

    Google Scholar 

  24. Roggenkamper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303–312

    Article  PubMed  CAS  Google Scholar 

  25. Shin HI, Han TR, Seo KI (2000) Effect of dilution volume of botulinum toxin A. J Korean Acad Phys Med Rehabil 28:67–76

    Google Scholar 

  26. Sommer Boris, Bergfeld D, Sattler G (2007) Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin – Klinische Erfahrungen und Empfehlungen langjähriger Anwender. JDDG 5 (Suppl 1):S1–S29

    Article  PubMed  Google Scholar 

  27. Trinidade de Almeida AR, Marques E, de Almeide J et al (2007) Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 33 (1 Spec NO.):S37–S43

    Google Scholar 

  28. Wohlfarth K, Müller C, Sassin I et al (2007) Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins. Clin Neuropharmacol 30(2):86–94

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Dermatologikum Hamburg, Stephansplatz 5, 20354, Hamburg, Deutschland

    W. Prager, L. Brocatti & V. Steinkraus

  2. SCIderm GmbH, Hamburg, Deutschland

    I. Zschocke, C. Reich & K. Henning

Authors
  1. W. Prager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Zschocke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Reich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Brocatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Henning
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Steinkraus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Prager.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prager, W., Zschocke, I., Reich, C. et al. Beeinflusst die Verdünnung das kosmetische Ergebnis von BoNT/A?. Hautarzt 60, 815–820 (2009). https://doi.org/10.1007/s00105-009-1840-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-009-1840-z

Schlüsselwörter

Keywords

Search

Navigation